Centessa Pharmaceuticals (CNTA) EBITDA Margin (2025)
Centessa Pharmaceuticals (CNTA) reported EBITDA Margin of 188.49% for Q1 2025.
Centessa Pharmaceuticals (CNTA) EBITDA Margin (2025) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 1 years of EBITDA Margin data on file, last reported at 188.49% in Q1 2025.
- EBITDA Margin for Q1 2025 came in at 188.49%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 1326.87% (changed N/A YoY), and the FY2025 annual result was 1326.87%, changed N/A from the prior year.
- EBITDA Margin was little changed at 188.49% in Q1 2025 per CNTA's latest filing.
- Over five years, EBITDA Margin peaked at 188.49% in Q1 2025 and troughed at 188.49% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -188.49% |